Post hoc analysis reveals KarXT reduces negative symptoms in acute schizophrenia, suggesting therapeutic effects occur independently of improvements in other symptom domains.
Participants with prominent NS revealed greater improvement of NS following KarXT therapy than the full sample that persisted after accounting for positive and other symptoms. While these findings must be interpreted with caution, they are consistent with the possibility that NS improvements associated with KarXT are not secondary to improvements in other symptom domains and support further investigation in larger, stable outpatient studies.
No takes yet. Share an insight, caveat, or question.
Horan et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: